The BioPharm Brief: Priority Review, ADC Progress, and New Frontiers in Fibrosis

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's stories span ophthalmology, oncology, and nephrology, but they share a common theme. Biopharma companies continue to push biologic therapies into new indications while improving convenience for patients and expanding treatment options for diseases with significant unmet need.

We begin with Genentech, where the FDA has granted Priority Review to the supplemental Biologics License Application for Enspryng (satralizumab) for thyroid eye disease. If approved, the IL-6 receptor inhibitor would become the first and only at home subcutaneous treatment for the condition, giving patients an alternative to infusion based therapies. The application is supported by data from the global Phase III SatraGO-1 and SatraGO-2 studies, which demonstrated clinically meaningful improvements in proptosis, disease activity, and double vision. The FDA is expected to make a decision by October 15, 2026.

Next, ADC Therapeutics announced completion of patient enrollment in the Phase Ib LOTIS 7 trial evaluating Zynlonta in combination with glofitamab for patients with relapsed or refractory diffuse large B cell lymphoma. The study is assessing whether pairing an antibody drug conjugate with a CD20 bispecific antibody can improve outcomes in patients whose disease has returned or progressed after previous therapies. Initial safety and efficacy data are expected later this year.

Finally, Mediar Therapeutics has dosed the first participant in a phase I study evaluating MTX-439, a first in class monoclonal antibody targeting SMOC2 for chronic kidney disease associated fibrosis. Rather than addressing symptoms, the therapy is designed to interrupt fibrotic signaling pathways that contribute to progressive kidney damage. The study represents an early clinical milestone for a novel mechanism that could eventually have applications beyond kidney disease in other fibrotic conditions.

Whether improving patient convenience, exploring combination biologics, or advancing entirely new therapeutic targets, these stories illustrate how innovation continues to expand across the biologics pipeline.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

• Genentech's Priority Review could lead to the first self administered biologic treatment for thyroid eye disease.
• ADC Therapeutics has completed enrollment in a key combination trial pairing an ADC with a bispecific antibody in relapsed lymphoma.
• Mediar Therapeutics has entered the clinic with a first in class anti SMOC2 antibody designed to address fibrosis in chronic kidney disease.